Medpace Holdings (MEDP) EBITDA (2015 - 2026)

Medpace Holdings (MEDP) has reported EBITDA for 12 consecutive years, with $148.3 million the latest figure, recorded in Q1 2026.

• EBITDA for Q1 2026 came in at $148.3 million, up 23.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $590.2 million (up 21.89% YoY), and the FY2025 annual result was $562.1 million, up 18.43% from the prior year.
• EBITDA was $148.3 million for Q1 2026 at Medpace Holdings, down from $160.2 million in the prior quarter.
• Over five years, EBITDA peaked at $160.2 million in Q4 2025 and troughed at $64.9 million in Q2 2022.
• Average EBITDA over 5 years is $108.5 million, with a median of $110.7 million recorded in 2024.
• Year-over-year, EBITDA surged 43.29% in 2022 and advanced 8.6% in 2025.
• Over 5 years, EBITDA stood at $81.5 million in 2022, then climbed by 15.03% to $93.7 million in 2023, then jumped by 41.36% to $132.5 million in 2024, then climbed by 20.88% to $160.2 million in 2025, then declined by 7.45% to $148.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $148.3 million in Q1 2026, $160.2 million in Q4 2025, and $148.6 million in Q3 2025.